Amundi Raises Stock Position in Zoetis Inc. (NYSE:ZTS)

Amundi lifted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 46.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,748,719 shares of the company's stock after purchasing an additional 867,993 shares during the period. Amundi owned about 0.61% of Zoetis worth $453,355,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of ZTS. Naviter Wealth LLC purchased a new stake in Zoetis during the fourth quarter valued at approximately $332,000. Intellectus Partners LLC lifted its position in Zoetis by 25.4% during the fourth quarter. Intellectus Partners LLC now owns 5,728 shares of the company's stock valued at $933,000 after acquiring an additional 1,162 shares during the last quarter. NS Partners Ltd lifted its position in Zoetis by 7.2% during the fourth quarter. NS Partners Ltd now owns 177,698 shares of the company's stock valued at $28,952,000 after acquiring an additional 11,910 shares during the last quarter. Banco Santander S.A. lifted its position in Zoetis by 9.8% during the fourth quarter. Banco Santander S.A. now owns 16,711 shares of the company's stock valued at $2,723,000 after acquiring an additional 1,489 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich lifted its position in Zoetis by 2.5% during the fourth quarter. Bank Julius Baer & Co. Ltd Zurich now owns 524,035 shares of the company's stock valued at $90,567,000 after acquiring an additional 12,677 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company's stock.

Remove Ads

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Barclays upped their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price target on the stock. Leerink Partners assumed coverage on shares of Zoetis in a research note on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target on the stock. Piper Sandler upped their price target on shares of Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a research note on Thursday, February 27th. Finally, Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $215.90.

Zoetis Stock Performance

NYSE ZTS traded up $3.09 during mid-day trading on Friday, reaching $170.34. 3,296,788 shares of the stock were exchanged, compared to its average volume of 3,274,650. The business's 50 day moving average is $166.72 and its 200-day moving average is $176.74. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.33. The company has a market capitalization of $76.28 billion, a P/E ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's dividend payout ratio is currently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.